Mutating factor VIII: Lessons from structure to function

Blood Reviews

Volumn 19, Issue 1, 2005, Pages 15-27

  Fay, Philip J ^a   Jenkins, P Vincent ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

CRM+ hemophilia; Factor IXa; Factor VIII; Factor VIIIa; Intrinsic factor Xase; Site directed mutagenesis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9A; INTRINSIC FACTOR; LIGAND; METAL ION; PHOSPHOLIPID; PROTEIN C;

ANTIGENICITY; BINDING SITE; BLOOD CLOTTING; CATABOLISM; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; IMMUNOGENICITY; LIVER CLEARANCE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW;

EID: 9644274261     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2004.02.003     Document Type: Article

References (88)

1. Gitschier J., Wood W.I., Goralka T.M., Wion K.L., Chen E.Y., Eaton D.H., et al. Characterization of the human factor VIII gene. Nature. 312:1984;326-330
2. Wood W.I., Capon D.J., Simonsen C.C., Eaton D.L., Gitschier J., Keyt B., et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 312:1984;330-337
3. Toole J.J., Knopf J.L., Wozney J.M., Sultzman L.A., Buecker J.L., Pittman D.D., et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 312:1984;342-347
4. Kemball-Cook G., Tuddenham E.G.D., Wacey A.I. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 26:1998;216-219
5. Wakabayashi H., Koszelak M.E., Mastri M., Fay P.J. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry. 40:2001;10293-10300
6. Fay P.J. Reconstitution of human factor VIII from isolated subunits. Arch. Biochem. Biophys. 262:1988;525-531
7. Sudhakar K., Fay P.J. Exposed hydrophobic sites in factor VIII and isolated subunits. J. Biol. Chem. 271:1996;23015-23021
8. Bihoreau N., Pin S., Kersabiec A.M.D., Vodot F., Fontaine-Aupart M.P. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-ΔII. Eur. J. Biochem. 220:1994;41-48
9. Tagliavacca L., Moon N., Dunham W.R., Kaufman R.J. Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII. J. Biol. Chem. 272:1997;27428-27434
10. Vehar G.A., Keyt B., Eaton D., Rodriguez H., O'Brien D.P., Rotblat F., et al. Structure of human factor VIII. Nature. 312:1984;337-342
11. Pemberton S., Lindley P., Zaitsev V., Card G., Tuddenham E.G., Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 89:1997;2413-2421
12. Wakabayashi H., Zhou Q., Fay P.J. Copper binding site(s) in factor VIII involved in the regulation of cofactor specific activity. J. Thromb. Haemost. (Suppl.):2003;OC112
13. 2+-dependent complex of fragments bound to phospholipid. J. Biol. Chem. 276:2001;19929-19936
14. Krishnaswamy S., Russell G.D., Mann K.G. The reassociation of factor Va from its isolated subunits. J. Biol. Chem. 264:1989;3160-3168
15. Wakabayashi H., Schmidt K.M., Fay P.J. Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity. Biochemistry. 41:2002;8485-8492
16. 2+ binding site required for cofactor activity. J. Biol. Chem. 279:2004;12677-12684
17. 2+ binding to factor VIII subunits and its effect on cofactor activity. Biochemistry. 42:2003;145-153
18. Fay P.J. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 18:2004;1-15
19. Barrowcliffe T.W. Comparisons of one-stage and two-stage assays of Factor VIII:C. Scand. J. Haematol. 41(Suppl.):1984;39-54
20. Duncan E.M., Duncan B.M., Tunbridge L.J., Lloyd J.V. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br. J. Haematol. 87:1994;846-848
21. Rudzki Z., Duncan E.M., Casey G.J., Neumann M., Favaloro E.J., Lloyd J.V. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br. J. Haematol. 94:1996;400-406
22. Pipe S.W., Eickhorst A.N., McKinley S.H., Saenko E.L., Kaufman R.J. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation. evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood. 93:1999;176-183
23. Pipe S.W., Saenko E.L., Eickhorst A.N., Kemball-Cook G., Kaufman R.J. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood. 97:2001;685-691
24. Hakeos W.H., Miao H., Sirachainan N., Kemball-Cook G., Saenko E.L., Kaufman R.J., et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb. Haemost. 88:2002;781-787
25. Lenting P.J., van Mourik J.A., Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 92:1998;3983-3996
26. Saenko E.L., Ananyeva N.M., Tuddenham E.G., Kemball-Cook G. Factor VIII - novel insights into form and function. Br. J. Haematol. 119:2002;323-331
27. Leyte A., Verbeet M.P., Brodniewicz-Proba T., Van Mourik J.A., Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem. J. 257:1989;679-683
28. Shima M., Scandella D., Yoshioka A., Nakai H., Tanaka I., Kamisue S., et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb. Haemost. 69:1993;240-246
29. Saenko E.L., Scandella D. The acidic region of the Factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J. Biol. Chem. 272:1997;18007-18014
30. Jacquemin M., Benhida A., Peerlinck K., Desqueper B., Vander Elst L., Lavend'homme R., et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 95:2000;156-163
31. Leyte A., van Schijndel H.B., Niehrs C., Huttner W.B., Verbeet M.P., Mertens K., et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J. Biol. Chem. 266:1991;740-746
32. Schwaab R., Oldenburg J., Schwaab U., Johnson D.J., Schmidt W., Olek K., et al. Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br. J. Haematol. 91:1995;458-464
33. Pratt K.P., Shen B.W., Takeshima K., Davie E.W., Fujikawa K., Stoddard B.L. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 402:1999;439-442
34. Liu M.L., Shen B.W., Nakaya S., Pratt K.P., Fujikawa K., Davie E.W., et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood. 96:2000;979-987
35. Pieters J., Lindhout T., Hemker H.C. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood. 74:1989;1021-1024
36. Fay P.J., Mastri M., Koszelak M.E., Wakabayashi H. Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa. J. Biol. Chem. 276:2001;12434-12439
37. Lollar P., Hill-Eubanks D.C., Parker C.G. Association of the factor VIII light chain with von Willebrand factor. J. Biol. Chem. 263:1988;10451-10455
38. Regan L.M., Fay P.J. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J. Biol. Chem. 270:1995;8546-8552
39. Donath M.S., Lenting P.J., van Mourik J.A., Mertens K. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J. Biol. Chem. 270:1995;3648-3655
40. Orcutt S.J., Pietropaolo C., Krishnaswamy S. Extended interactions with prothrombinase enforce affinity and specificity for its macromolecular substrate. J. Biol. Chem. 277:2002;46191-46196
41. Barrow R.T., Healey J.F., Lollar P. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J. Biol. Chem. 269:1994;593-598
42. Esmon C.T., Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J. Biol. Chem. 271:1996;13882-13887
43. Myles T., Yun T.H., Leung L.L. Structural requirements for the activation of human factor VIII by thrombin. Blood. 100:2002;2820-2826
44. Goodeve A.C., Hinks J.L., Nesbitt I.M., Sampson B., Burgess C., Khair K., et al. Unusual discrepant factor VIII:C assays in heamoplilia A in patients with Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb. Haemost. (Suppl.):2001;P1370
45. Mumford A.D., Laffan M., O'Donnell J., McVey J.H., Johnson D.J., Manning R.A., et al. A Tyr346. → Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy Br. J. Haematol. 118:2002;589-594
46. Roelse J.C., de Laaf R.T.M., Mertens K., van Mourik J.A., Oldenburg J.J.V. Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a Glu720 to Lys substitution in factor VIII. Thromb. Haemost. 82(Suppl.):1999;2
47. Michnick D.A., Pittman D.D., Wise R.J., Kaufman R.J. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J. Biol. Chem. 269:1994;20095-20102
48. Schmidt A.E., Bajaj S.P. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc. Med. 13:2003;39-45
49. Lenting P.J., Donath M.J., van Mourik J.A., Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J. Biol. Chem. 269:1994;7150-7155
50. Van Stempvoort G., Fribourg C., Celie P.H.N., Lenting P.J., Mertens K. Factor VIII-factor IX interactions probed by chimeric factor VIII/V variants: complex assembly and cofactor function involve different residues within the A3 domain region 1803-1818. J. Thromb. Haemost. (Suppl.):2003;OC111
51. Regan L.M., Lamphear B.J., Huggins C.F., Walker F.J., Fay P.J. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J. Biol. Chem. 269:1994;9445-9452
52. Fay P.J., Beattie T., Huggins C.F., Regan L.M. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J. Biol. Chem. 269:1994;20522-20527
53. Aly A.M., Higuchi M., Kasper C.K., Kazazian H.H. Jr., Antonarakis S.E., Hoyer L.W. Hemophilia A due to mutations that create new N-glycosylation sites. Proc. Natl. Acad. Sci. USA. 89:1992;4933-4937
54. Amano K., Sarkar R., Pemberton S., Kemball-Cook G., Kazazian H.H. Jr., Kaufman R.J. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood. 91:1998;538-548
55. Jenkins P.V., Freas J., Schmidt K.M., Zhou Q., Fay P.J. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood. 100:2002;501-508
56. Bajaj S.P., Schmidt A.E., Mathur A., Padmanabhan K., Zhong D., Mastri M., et al. Factor IXa:factor VIIIa interaction. helix 330-338 of factor IXa interacts with residues 558-565 and spatially adjacent regions of the A2 subunit of factor VIIIa. J. Biol. Chem. 276:2001;16302-16309
57. Mathur A., Bajaj S.P. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J. Biol. Chem. 274:1999;18477-18486
58. Jenkins PV, Dill J, Zhou Q, Fay PJ. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry, [in press]
59. Mertens K., van Wijngaarden A., Bertina R.M., Veltkamp J.J. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII. Thromb. Haemost. 54:1985;650-653
60. Healey J.F., Lubin I.M., Nakai H., Saenko E.L., Hoyer L.W., Scandella D., et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J. Biol. Chem. 270:1995;14505-14509
61. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost [in press]
62. Fuentes-Prior P., Fujikawa K., Pratt K.P. New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr. Protein Peptide Sci. 3:2002;313-339
63. Gilbert G.E., Kaufman R.J., Arena A.A., Miao H., Pipe S.W. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J. Biol. Chem. 277:2002;6374-6481
64. Lenting P.J., Neels J.G., van den Berg B.M., Clijsters P.P., Meijerman D.W., Pannekoek H., et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J. Biol. Chem. 274:1999;23734-23739
65. Saenko E.L., Yakhyaev A.V., Mikhailenko I., Strickland D.K., Sarafanov A.G. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J. Biol. Chem. 274:1999;37685-37692
66. Turecek P.L., Schwarz H.P., Binder B.R. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood. 95:2000;3637-3638
67. Bovenschen N., Boertjes R.C., van Stempvoort G., Voorberg J., Lenting P.J., Meijer A.B., et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J. Biol. Chem. 278:2003;9370-9377
68. Sarafanov A.G., Ananyeva N.M., Shima M., Saenko E.L. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J. Biol. Chem. 276:2001;11970-11979
69. Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sanguinis. 77:1999;17-20
70. Lollar P., Healey J.F., Barrow R.T., Parker E.T. Factor VIII inhibitors. Adv. Exp. Med. Biol. 489:2001;65-73
71. Saenko E.L., Ananyeva N.M., Kouiavskaia D.V., Khrenov A.V., Anderson J.A., Shima M., et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia. 8:2002;1-11
72. Scandella D., DeGraaf Mahoney S., Mattingly M., Roeder D., Timmons L., Fulcher C.A. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. [published erratum appears in Proc Natl Acad Sci USA 1989 Feb;86(4):1387] Proc. Natl. Acad. Sci. USA. 85:1988;6152-6156
73. Lubin I.M., Healey J.F., Scandella D., Runge M.S., Lollar P. Elimination of a major inhibitor epitope in factor VIII. J. Biol. Chem. 269:1994;8639-8641
74. Fay P.J., Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J. Biol. Chem. 274:1999;29826-29830
75. Lollar P., Parker E.T., Curtis J.E., Helgerson S.L., Hoyer L.W., Scott M.E., et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J. Clin. Invest. 93:1994;2497-2504
76. Lubin I.M., Healey J.F., Barrow R.T., Scandella D., Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J. Biol. Chem. 272:1997;30191-30195
77. Healey J.F., Barrow R.T., Tamim H.M., Lubin I.M., Shima M., Scandella D., et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 92:1998;3701-3709
78. Barrow R.T., Healey J.F., Jacquemin M.G., Saint-Remy J.M., Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 97:2001;169-174
79. Spiegel P.C. Jr., Jacquemin M., Saint-Remy J.M., Stoddard B.L., Pratt K.P. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 98:2001;13-19
80. Kaufman R.J., Pipe S.W. Can we improve on nature? "Super molecules" of factor VIII. Haemophilia. 4:1998;370-379
81. Saenko E.L., Ananyeva N.M., Moayeri M., Ramezani A., Hawley R.G. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr. Gene Therapy. 3:2003;27-41
82. Saenko E.L., Ananyeva N.M., Shima M., Hauser C.A.E., Pipe S.W. The future of recombinant coagulation factors. J. Thromb. Haemost. 1:2003;922-930
83. Lenting P.J., van de Loo J.W., Donath M.J., van Mourik J.A., Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J. Biol. Chem. 271:1996;1935-1940
84. Pipe S.W., Kaufman R.J. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc. Natl. Acad. Sci. USA. 94:1997;11851-11856
85. Gale A.J., Pellequer J.-L. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J. Thromb. Haemost. 1:2003;1966-1971
86. Barrow R.T., Healey J.F., Gailani D., Scandella D., Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood. 95:2000;564-568
87. Stoilova-McPhie S., Villoutreix B.O., Mertens K., Kemball-Cook G., Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 99:2002;1215-1223
88. Brandstetter H., Bauer M., Huber R., Lollar P., Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. USA. 92:1995;9796-9800